tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Samantha Semenkow, 93 are a BUY (86.11%), 15 are a HOLD (13.89%).
Analyst Samantha Semenkow, currently employed at CITI, carries an average stock price target met ratio of 33.83% that have a potential upside of 40.15% achieved within 100 days. Previously, Samantha Semenkow worked at MONNESS CRESPI & HARDT.
Samantha Semenkow’s has documented 214 price targets and ratings displayed on 28 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 10-Aug-2026.
Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for LRMR (LARIMAR THERAPEUTICS) at 2/13/2024. The price target of $10 was fulfilled within 1 day with a profit of $1.26 (14.42%) receiving and performance score of 144.16.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 25-Apr-2026
$50
$18.2 (57.23%)
$46
12 days ago
(21-Sep-2026)
1/3 (33.33%)
$16.05 (47.28%)
73
Hold Since 01-Dec-2022
$34
$2.2 (6.92%)
$31
1 months 26 days ago
(07-Aug-2026)
9/10 (90%)
$1.73 (5.36%)
123
Buy Since 05-Mar-2026
$52
$20.2 (63.52%)
$46
2 months 2 days ago
(31-Jul-2026)
1/3 (33.33%)
$21.98 (73.22%)
215
Buy Since 05-Jan-2024
$39
$7.2 (22.64%)
$41
2 months 2 days ago
(31-Jul-2026)
10/12 (83.33%)
$8.98 (29.91%)
95
Buy Since 24-Feb-2025
$55
$23.2 (72.96%)
$52
2 months 3 days ago
(30-Jul-2026)
0/12 (0%)
$22.25 (67.94%)
Which stock is Samantha Semenkow most bullish on?
Which stock is Samantha Semenkow most reserved on?
What Year was the first public recommendation made by Samantha Semenkow?
